MedTrace Logo

Hemoperfusion Efferon СT for the Treatment of Patients With Acute Pancreatitis

NCT05695001 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2024-02-21

No results posted yet for this study

Summary

Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF). Due to the lack of etiological therapy, the treatment of acute pancreatitis is predominantly symptomatic.

Severity and mortality are associated with early systemic inflammatory response syndrome (SIRS) and septic complications at a later stage of the disease.

With regard to the pronounced inflammatory response ("cytokine storm") during the early phase of endogenous intoxication of acute pancreatitis, extracorporeal removal of cytokines is a promising therapeutic approach.

This prospective study examines the effect of early extracorporeal sorption of cytokines using the Efferon CT device on the severity of clinical symptoms of endogenous intoxication in acute pancreatitis and aseptic pancreatic necrosis.

Conditions

  • Acute Pancreatitis With Uninfected Necrosis, Unspecified

Interventions

DEVICE

Efferon CT

Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross-linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.

Sponsors & Collaborators

  • Efferon JSC

    lead INDUSTRY

Principal Investigators

  • Vladimir Kiselev, PhD, MD · N. V. Sklifosovsky Moscow Research Institute of Emergency, Moscow, Russia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-09-30
Completion
2023-11-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05695001 on ClinicalTrials.gov